Traws Pharma (NASDAQ: TRAW) reported no revenue and a net loss of $3.0 million, or $0.16 per basic and diluted common share, for the quarter ended June 30, 2026. The company reported $5.0 million in cash and cash equivalents at quarter-end.
The company is preparing a revised toxicology package for an expected MHRA resubmission for tivoxavir marboxil at the end of the third quarter of 2026. Traws also said it is preparing a response to resolve the FDA clinical hold on the U.S. IND for the program.
- Q2 revenue was $0, compared with $2.7 million in the prior-year quarter.
- Research and development expense was $1.1 million, versus $2.3 million a year earlier.
- General and administrative expense was $3.5 million, compared with $1.7 million in Q2 2025.
- The April 2026 financing delivered $10.0 million in upfront proceeds and may provide up to $50.0 million in additional financing, subject to milestones and investor participation.
- Traws had 15,368,277 common shares outstanding as of August 13, 2026.
$TRAW Insider Trading Activity
$TRAW insiders have traded $TRAW stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TRAW stock by insiders over the last 6 months:
- ADVISORS LLC ORBIMED purchased 597,729 shares for an estimated $998,207
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$TRAW Hedge Fund Activity
We have seen 16 institutional investors add shares of $TRAW stock to their portfolio, and 19 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 400,000 shares (+121.2%) to their portfolio in Q1 2026, for an estimated $732,000
- SPHERA FUNDS MANAGEMENT LTD. added 398,486 shares (+inf%) to their portfolio in Q2 2026, for an estimated $336,043
- DAUNTLESS INVESTMENT GROUP, LLC removed 336,424 shares (-80.7%) from their portfolio in Q2 2026, for an estimated $283,706
- SQUADRON CAPITAL MANAGEMENT LLC removed 201,826 shares (-28.3%) from their portfolio in Q1 2026, for an estimated $369,341
- HRT FINANCIAL LP added 91,220 shares (+inf%) to their portfolio in Q2 2026, for an estimated $76,925
- PALUMBO WEALTH MANAGEMENT LLC removed 61,175 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $51,588
- BOOTHBAY FUND MANAGEMENT, LLC removed 60,600 shares (-31.2%) from their portfolio in Q2 2026, for an estimated $51,103
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
